Kalra Sanjay, Gupta Yashdeep
Department of Endocrinology, 1Bharti Hospital, Karnal, 2All India Institute of Medical Sciences, New Delhi, India.
J Pak Med Assoc. 2016 Mar;66(3):357-9.
This brief review describes the potential non-glycaemic effects and benefits of glucagon like peptide 1 receptor agonists (GLP1RA). It lists various indications in which this class of drugs has been used, and explains the rationale behind this use. The potential uses of GLP1RA extend across the entire spectrum of endocrinology and metabolism, from hypothalamic obesity to non-alcoholic steatohepatitis (NASH) to polycystic ovary syndrome (PCOS). The article also discusses and addresses endocrine-related concerns related to the GLP1RAs.
本简要综述描述了胰高血糖素样肽1受体激动剂（GLP1RA）的潜在非血糖效应和益处。它列出了使用这类药物的各种适应症，并解释了这种使用背后的基本原理。GLP1RA的潜在用途涵盖了内分泌学和代谢的整个领域，从下丘脑性肥胖到非酒精性脂肪性肝炎（NASH）再到多囊卵巢综合征（PCOS）。本文还讨论并解决了与GLP1RA相关的内分泌问题。
